National Academies Press: OpenBook
« Previous: 6 Final Remarks
Suggested Citation:"References." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

References

Baselga, J., D. Tripathy, J. Mendelsohn, S. Baughman, C. C. Benz, L. Dantis, N. T. Sklarin, A. D. Seidman, C. A. Hudis, J. Moore, P. P. Rosen, T. Twaddell, I. C. Henderson, and L. Norton. 1999. Phase II study of weekly intravenous trastuzumab (herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Seminars in Oncology 26(4 Suppl 12):78-83.

Benowitz, N. L., O. F. Pomerleau, C. S. Pomerleau, and P. Jacob, 3rd. 2003. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine and Tobacco Research 5(5):621-624.

Berry, D. A., K. A. Cronin, S. K. Plevritis, D. G. Fryback, L. Clarke, M. Zelen, J. S. Mandelblatt, A. Y. Yakovlev, J. D. Habbema, and E. J. Feuer. 2005. Effect of screening and adjuvant therapy on mortality from breast cancer. New England Journal of Medicine 353(17):1784-1792.

Berry, D. A., C. Cirrincione, I. C. Henderson, M. L. Citron, D. R. Budman, L. J. Goldstein, S. Martino, E. A. Perez, H. B. Muss, L. Norton, C. Hudis, and E. P. Winer. 2006. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. Journal of the American Medical Association 295(14):1658-1667.

Brass, E. P. 2010. The gap between clinical trials and clinical practice: The use of pragmatic clinical trials to inform regulatory decision making. Clinical Pharmacology & Therapeutics 87(3):351-355.

de Jong, A. E., Y. M. Hendriks, J. H. Kleibeuker, S. Y. de Boer, A. Cats, G. Griffioen, F. M. Nagengast, F. G. Nelis, M. A. Rookus, and H. F. Vasen. 2006. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130(3):665-671.

Evans, W. K., A. Laupacis, K. Y. Gulenchyn, L. Levin, and M. Levine. 2009. Evidence-based approach to the introduction of positron emission tomography in Ontario, Canada. Journal of Clinical Oncology 27(33):5607-5613.

Goeree, R., and L. Levin. 2006. Building bridges between academic research and policy formulation: The PRUFE framework—an integral part of Ontario’s evidence-based HTPA process. Pharmacoeconomics 24(11):1143-1156.

Suggested Citation:"References." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

Gonzales, D., S. I. Rennard, M. Nides, C. Oncken, S. Azoulay, C. B. Billing, E. J. Watsky, J. Gong, K. E. Williams, and K. R. Reeves. 2006. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. Journal of the American Medical Association 296(1):47-55.

Harris, L., H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast, Jr. 2007. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology 25(33):5287-5312.

Imperiale, T. F., D. R. Wagner, C. Y. Lin, G. N. Larkin, J. D. Rogge, and D. F. Ransohoff. 2000. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. New England Journal of Medicine 343(3):169-174.

Imperiale, T. F., E. A. Glowinski, C. Lin-Cooper, G. N. Larkin, J. D. Rogge, and D. F. Ransohoff. 2008. Five-year risk of colorectal neoplasia after negative screening colonoscopy. New England Journal of Medicine 359(12):1218-1224.

IOM (Institute of Medicine). 2010. The value of genetic and genomic technologies: Workshop summary. Washington, DC: The National Academies Press.

IOM. 2011. Establishing precompetitive collaborations to stimulate genomics-driven product development: Workshop summary. Washington, DC: The National Academies Press.

Jarvinen, H. J., M. Aarnio, H. Mustonen, K. Aktan-Collan, L. A. Aaltonen, P. Peltomaki, A. D. L. Chapelle, and J. P. Mecklin. 2000. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5):829-834.

Lee, J. J., and E. Chu. 2007. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Clinical Colorectal Cancer 6 (Suppl 2):S42-S46.

Levin, L., R. Goeree, N. Sikich, B. Jorgensen, M. C. Brouwers, T. Easty, and C. Zahn. 2007. Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: The Ontario experience. International Journal of Technology Assessment in Health Care 23(3):299-309.

Malaiyandi, V., S. D. Goodz, E. M. Sellers, and R. F. Tyndale. 2006. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiology, Biomarkers & Prevention 15(10):1812-1819.

Marchionni, L., R. F. Wilson, S. S. Marinopoulos, A. C. Wolff, G. Parmigiani, E. B. Bass, and S. N. Goodman. 2008. Impact of gene expression profiling tests on breast cancer outcomes. Evidence report/technology assessment no. 160. (prepared by the Johns Hopkins University Evidence-Based Practice Center under contract no. 290-02-0018). Agency for Healthcare Research and Quality Publication No. 08-E002 January.

MAS (Medical Advisory Secretariat). 2010. Endovascular repair of abdominal aortic aneurysms in low surgical risk patients: Rapid review. Toronto, ON: Medical Advisory Secretariat. Available at http://www.health.gov.on.ca/english/providers/program/mas/tech/rapid/pdf/rr_evar_20100113.pdf (accessed March 24, 2011).

Moss, A. J., W. Shimizu, A. A. Wilde, J. A. Towbin, W. Zareba, J. L. Robinson, M. Qi, G. M. Vincent, M. J. Ackerman, E. S. Kaufman, N. Hofman, R. Seth, S. Kamakura, Y. Miyamoto, I. Goldenberg, M. L. Andrews, and S. McNitt. 2007. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 115(19):2481-2489.

Paik, S., S. Shak, G. Tang, C. Kim, J. Baker, M. Cronin, F. L. Baehner, M. G. Walker, D. Watson, T. Park, W. Hiller, E. R. Fisher, D. L. Wickerham, J. Bryant, and N. Wolmark. 2004a. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 351(27):2817-2826.

Suggested Citation:"References." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

Paik, S., S. Shak, G. Tang, C. Kim, J. Baker, M. Cronin, R. Baehner, M. Walker, D. Watson, J. Bryant, and N. Wolmark. 2004b. Risk classification of breast cancer patients by the recurrence score assay: Comparison to guidelines based on patient age, tumor size, and tumor grade. Paper read at 27th Annual San Antonio Breast Cancer Symposium, December 8-11, 2004, San Antonio, TX.

Paik, S., G. Tang, S. Shak, C. Kim, J. Baker, W. Kim, M. Cronin, F. L. Baehner, D. Watson, J. Bryant, J. P. Costantino, C. E. Geyer, Jr., D. L. Wickerham, and N. Wolmark. 2006. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of Clinical Oncology 24(23):3726-3734.

Palomaki, G. E., M. R. McClain, S. Melillo, H. L. Hampel, and S. N. Thibodeau. 2009. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genetics in Medicine 11(1):42-65.

Pencina, M. J., R. B. D’Agostino, Sr., R. B. D’Agostino, Jr., and R. S. Vasan. 2008. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Statistics in Medicine 27(2):157-172; discussion 207-212.

Pepe, M. S., H. Janes, G. Longton, W. Leisenring, and P. Newcomb. 2004. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. American Journal of Epidemiology 59(9):882-890.

Peto, R., J. Boreham, M. Clarke, C. Davies, and V. Beral. 2000. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355(9217):1822.

Ray, R., R. F. Tyndale, and C. Lerman. 2009. Nicotine dependence pharmacogenetics: Role of genetic variation in nicotine-metabolizing enzymes. Journal of Neurogenetics 23(3):252-261.

Roden, D. M. 2008. Clinical practice. Long-QT syndrome. New England Journal of Medicine 358(2):169-176.

Schmeler, K. M., H. T. Lynch, L. M. Chen, M. F. Munsell, P. T. Soliman, M. B. Clark, M. S. Daniels, K. G. White, S. G. Boyd-Rogers, P. G. Conrad, K. Y. Yang, M. M. Rubin, C. C. Sun, B. M. Slomovitz, D. M. Gershenson, and K. H. Lu. 2006. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. New England Journal of Medicine 354(3):261-269.

Shao, Y. Y. 2010. Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. Discovery Medicine 49(June 2010). Available at http://www.discoverymedicine.com/Yu-Yun-Shao/2010/06/19/gefitinib-or-erlotinib-in-the-treatment-of-advanced-non-smallcell-lung-cancer/(accessed March 25).

Simon, R. M., S. Paik, and D. F. Hayes. 2009. Use of archived specimens in evaluation of prognostic and predictive biomarkers. Journal of the National Cancer Institute 101(21):1446-1452.

Tarride, J. E., G. Blackhouse, G. De Rose, T. Novick, J. M. Bowen, R. Hopkins, D. O’Reilly, and R. Goeree. 2008. Cost-effectiveness analysis of elective endovascular repair compared with open surgical repair of abdominal aortic aneurysms for patients at a high surgical risk: A 1-year patient-level analysis conducted in Ontario, Canada. Journal of Vascular Surgery 48(4):779-787.

TEC (Blue Cross and Blue Shield Association Technology Evaluation Center). 2005. Gene expression profiling for managing breast cancer treatment. Technology Evaluation Center Assessment Program 20(3):1-5.

TEC. 2007. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer. Technology Evaluation Center Assessment Program 22(6):1-22.

TEC. 2008a. Gene expression profiling of breast cancer to select women for adjuvant chemotherapy. Technology Evaluation Center Assessment Program 22(13):1-8.

Suggested Citation:"References." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

TEC. 2008b. Genetic testing for long-QT syndrome. Technology Evaluation Center Assessment Program 22(9):1-5.

TEC. 2011. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer. Technology Evaluation Center Assessment Program 25(6):1-30.

Teutsch, S. M., L. A. Bradley, G. E. Palomaki, J. E. Haddow, M. Piper, N. Calonge, W. D. Dotson, M. P. Douglas, and A. O. Berg. 2009. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: Methods of the EGAPP working group. Genetics in Medicine 11(1):3-14.

Tu, J. V., J. Bowen, M. Chiu, D. T. Ko, P. C. Austin, Y. He, R. Hopkins, J. E. Tarride, G. Blackhouse, C. Lazzam, E. A. Cohen, and R. Goeree. 2007. Effectiveness and safety of drug-eluting stents in Ontario. New England Journal of Medicine 357(14):1393-1402.

Villanueva, J., D. R. Shaffer, J. Philip, C. A. Chaparro, H. Erdjument-Bromage, A. B. Olshen, M. Fleisher, H. Lilja, E. Brogi, J. Boyd, M. Sanchez-Carbayo, E. C. Holland, C. Cordon-Cardo, H. I. Scher, and P. Tempst. 2006. Differential exoprotease activities confer tumorspecific serum peptidome patterns. Journal of Clinical Investigation 116(1):271-284.

Wolff, A. C., M. E. Hammond, J. N. Schwartz, K. L. Hagerty, D. C. Allred, R. J. Cote, M. Dowsett, P. L. Fitzgibbons, W. M. Hanna, A. Langer, L. M. McShane, S. Paik, M. D. Pegram, E. A. Perez, M. F. Press, A. Rhodes, C. Sturgeon, S. E. Taube, R. Tubbs, G. H. Vance, M. van de Vijver, T. M. Wheeler, and D. F. Hayes. 2007. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology 25(1):118-145.

Zhu, C. Q., G. da Cunha Santos, K. Ding, A. Sakurada, J. C. Cutz, N. Liu, T. Zhang, P. Marrano, M. Whitehead, J. A. Squire, S. Kamel-Reid, L. Seymour, F. A. Shepherd, and M. S. Tsao. 2008. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology 26(26):4268-4275.

Zujewski, J. A., and L. Kamin. 2008. Trial assessing individualized options for treatment for breast cancer: The TAILORx trial. Future Oncology 4(5):603-610.

Suggested Citation:"References." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page 63
Suggested Citation:"References." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page 64
Suggested Citation:"References." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page 65
Suggested Citation:"References." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page 66
Next: Appendix A: Workshop Agenda »
Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary Get This Book
×
Buy Paperback | $29.00 Buy Ebook | $23.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Ten years after the sequencing of the human genome, scientists have developed genetic tests that can predict a person's response to certain drugs, estimate the risk of developing Alzheimer's disease, and make other predictions based on known links between genes and diseases. However, genetic tests have yet to become a routine part of medical care, in part because there is not enough evidence to show they help improve patients' health.

The Institute of Medicine (IOM) held a workshop to explore how researchers can gather better evidence more efficiently on the clinical utility of genetic tests. Generating Evidence for Genomic Diagnostic Test Development compares the evidence that is required for decisions regarding clearance, use, and reimbursement, to the evidence that is currently generated. The report also addresses innovative and efficient ways to generate high-quality evidence, as well as barriers to generating this evidence.

Generating Evidence for Genomic Diagnostic Test Development contains information that will be of great value to regulators and policymakers, payers, health-care providers, researchers, funders, and evidence-based review groups.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!